![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
2seventybio
Main focus: Novel cellular therapies for the treatment of cancer
Company stage: Clinical
Diseases: Cancer (undisclosed which programmes use gene editing)
Genome editing tool: megaTAL-based genome editing
Funding stage: Public (NASDAQ:TSVT)
Location: Cambridge, MA, USA
Website: https://www.2seventybio.com/
Pipeline: https://www.2seventybio.com/our-science
Gene editing Partnerships: Novo Nordisk
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_2seventybio_c97ce8f070_f7d6a8215b.png)
2seventy bio was recently formed as a spin-out company from bluebird bio. The company focuses on next generation cell-based therapies for the treatment of cancer. The company holds a priprietary megaTAL technology, which it applies for genomic engineering of its therapies. Currently, however, it is undisclosed which of the company's early phase programmes are actually incorporating the megaTAL technology.